MPN are characterized by a constitutive activation of JAK/STAT signaling pathway mediated by mutations in e.g., JAK2 gene leading to the phosphorylation of STAT3 and activation of downstream effectors, which are crucial for disease initiation and progression [3, 6]. Here, STAT3 is linked to myeloproliferative neoplasm.